Skip to main content

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Editors' pick

15-06-2018 | Rheumatoid arthritis | EULAR 2018 | News

Further evidence for the benefits of upadacitinib in patients with RA

Results from two phase III trials presented at the EULAR 2018 meeting in Amsterdam, the Netherlands, suggest that treatment with the Janus kinase inhibitor upadacitinib alone or in combination with conventional DMARDs may be beneficial for patients with rheumatoid arthritis.

06-04-2018 | Spondyloarthropathies | Feature | Article

At a glance: Trials of tofacitinib in spondyloarthritis

A quick-reference guide to the published and ongoing clinical trials of tofacitinib for the treatment of spondyloarthritis.

12-06-2018 | Physical activity | View from the clinic | Article

Incorporating exercise in the treatment of lupus and other rheumatic diseases: It's time!

In this piece, Sarah Patterson and Patricia Katz discuss the benefits of exercise, and the barriers to increasing physical activity, in patients with systemic lupus erythematosus.

Latest from across the site

22-06-2018 | Rheumatoid arthritis | News

Biologic treatment alone unlikely to improve mental health in RA patients

Pharmacotherapy for rheumatoid arthritis does not meaningfully improve mental health outcomes for the majority of patients, researchers report.


Arthritis Rheumatol 2018; Advance online publication

20-06-2018 | Lupus nephritis | EULAR 2018 | News

Abatacept fails to boost renal response rate in lupus nephritis

The addition of abatacept to standard therapy does not increase the rate of complete renal response among patients with lupus nephritis, phase III study findings show.

20-06-2018 | Juvenile idiopathic arthritis | EULAR 2018 | News

No increase in JIA-associated uveitis risk with etanercept treatment

Patients with juvenile idiopathic arthritis who are treated with etanercept do not have a higher risk for developing uveitis than those given methotrexate, results of a UK cohort study suggest.


EULAR 2018 meeting; Amsterdam, the Netherlands

20-06-2018 | Systemic lupus erythematosus | EULAR 2018 | News

Encouraging long-term safety findings for belimumab in SLE

Belimumab, a B-lymphocyte stimulator specific inhibitor used for the treatment of systemic lupus erythematosus, has a stable safety profile over 8 years of follow-up, with no new safety signals observed, report researchers.

19-06-2018 | Rheumatoid arthritis | EULAR 2018 | News

Depression and anxiety closely linked to RA disease activity

Depression and anxiety are significant comorbidities in early rheumatoid arthritis and levels change in line with disease activity, shows research.

18-06-2018 | Rheumatoid arthritis | EULAR 2018 | News

News in brief

Synovial gene signatures associated with later RA onset

Researchers have found molecular changes appearing in the synovial tissue that precede rheumatoid arthritis development and may tell us more about the pathogenesis of the disease and treatment targets.

Meet our Editorial Board

New Content Item Meet our Advisory Board

image credits